Shraddha Sapkota1, Roger A Dixon1,2. 1. Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada. 2. Department of Psychology, University of Alberta, Edmonton, Canada.
Abstract
BACKGROUND: Trajectories of complex neurocognitive phenotypes in preclinical aging may be produced differentially through selective and interactive combinations of genetic risk. OBJECTIVE: We organize three possible combinations into a "network" of genetic risk indices derived from polymorphisms associated with normal and impaired cognitive aging, as well as Alzheimer's disease (AD). Specifically, we assemble and examine three genetic clusters relevant to non-demented cognitive trajectories: 1) Apolipoprotein E (APOE), 2) a Cognitive Aging Genetic Risk Score (CA-GRS; Catechol-O-methyltransferase + Brain-derived neurotrophic factor), and 3) an AD-Genetic Risk Score (AD-GRS; Clusterin + Complement receptor 1 + Phosphatidylinositol-binding clathrin assembly protein). METHOD: We use an accelerated longitudinal design (n = 634; age range = 55-95 years) to test whether AD-GRS (low versus high) moderates the effect of increasing CA-GRS risk on executive function (EF) performance and change as stratified by APOE status (ɛ4+ versus ɛ4-). RESULTS: APOEɛ4 carriers with high AD-GRS had poorer EF performance at the centering age (75 years) and steeper 9-year decline with increasing CA-GRS but this association was not present in APOEɛ4 carriers with low AD-GRS. CONCLUSIONS: APOEɛ4 carriers with high AD-GRS are at elevated risk of cognitive decline when they also possess higher CA-GRS risk. Genetic risk from both common cognitive aging and AD-related indices may interact in intensification networks to differentially predict (1) level and trajectories of EF decline and (2) potential selective vulnerability for transitions into impairment and dementia.
BACKGROUND: Trajectories of complex neurocognitive phenotypes in preclinical aging may be produced differentially through selective and interactive combinations of genetic risk. OBJECTIVE: We organize three possible combinations into a "network" of genetic risk indices derived from polymorphisms associated with normal and impaired cognitive aging, as well as Alzheimer's disease (AD). Specifically, we assemble and examine three genetic clusters relevant to non-demented cognitive trajectories: 1) Apolipoprotein E (APOE), 2) a Cognitive Aging Genetic Risk Score (CA-GRS; Catechol-O-methyltransferase + Brain-derived neurotrophic factor), and 3) an AD-Genetic Risk Score (AD-GRS; Clusterin + Complement receptor 1 + Phosphatidylinositol-binding clathrin assembly protein). METHOD: We use an accelerated longitudinal design (n = 634; age range = 55-95 years) to test whether AD-GRS (low versus high) moderates the effect of increasing CA-GRS risk on executive function (EF) performance and change as stratified by APOE status (ɛ4+ versus ɛ4-). RESULTS:APOEɛ4 carriers with high AD-GRS had poorer EF performance at the centering age (75 years) and steeper 9-year decline with increasing CA-GRS but this association was not present in APOEɛ4 carriers with low AD-GRS. CONCLUSIONS:APOEɛ4 carriers with high AD-GRS are at elevated risk of cognitive decline when they also possess higher CA-GRS risk. Genetic risk from both common cognitive aging and AD-related indices may interact in intensification networks to differentially predict (1) level and trajectories of EF decline and (2) potential selective vulnerability for transitions into impairment and dementia.
Authors: Brit-Maren M Schjeide; Cathrin Schnack; Jean-Charles Lambert; Christina M Lill; Julia Kirchheiner; Hayrettin Tumani; Markus Otto; Rudolph E Tanzi; Hans Lehrach; Philippe Amouyel; Christine A F von Arnim; Lars Bertram Journal: Arch Gen Psychiatry Date: 2011-02
Authors: E Rodríguez-Rodríguez; P Sánchez-Juan; J L Vázquez-Higuera; I Mateo; A Pozueta; J Berciano; S Cervantes; D Alcolea; P Martínez-Lage; J Clarimón; A Lleó; P Pastor; O Combarros Journal: J Neural Transm (Vienna) Date: 2012-11-20 Impact factor: 3.575
Authors: Helen Crehan; Patrick Holton; Selina Wray; Jennifer Pocock; Rita Guerreiro; John Hardy Journal: Immunobiology Date: 2011-07-23 Impact factor: 3.144
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: AmanPreet Badhwar; G Peggy McFall; Shraddha Sapkota; Sandra E Black; Howard Chertkow; Simon Duchesne; Mario Masellis; Liang Li; Roger A Dixon; Pierre Bellec Journal: Brain Date: 2020-05-01 Impact factor: 13.501
Authors: Shraddha Sapkota; Joel Ramirez; Donald T Stuss; Mario Masellis; Sandra E Black Journal: Alzheimers Res Ther Date: 2018-09-05 Impact factor: 6.982
Authors: Shraddha Sapkota; Tao Huan; Tran Tran; Jiamin Zheng; Richard Camicioli; Liang Li; Roger A Dixon Journal: Front Aging Neurosci Date: 2018-10-02 Impact factor: 5.750